Bull case
Microbot Medical is positioned to benefit from a compelling adoption thesis built on the LIBERTY system’s FDA-cleared, single-use robotic platform, which directly addresses the American Medical Association’s end-2025 public policy on occupational radiation exposure and specialty-society concerns about lead-apron strain. The company’s early traction during LMR across multiple healthcare systems, including Emory Healthcare, suggests a shorter sales cycle than traditional robots, while the account base of roughly 85 units sold through 1H26 across 10 to 11 accounts indicates room for utilization to deepen as operators progress through seven to ten cases and do not revert. Although 3Q26 and 4Q26 revenue are modeled at $400K and $600K and margin expansion is delayed, the expected cost-of-revenue improvement, broader U.S. territory rollout, and international clearances support a durable longer-term growth and gross-margin inflection.